220475-06-9

Upstream product

• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 
• 100-39-0 benzyl bromide 
• 66831-17-2 (2S,4R)-methyl 4-(benzyloxy)pyrrolidine-2-carboxylate hydrochloride 
• 51-35-4 4R-4-hydroxyproline 

Downstream Products

• 220475-22-9 (2S,4R,1'R)-N-benzyl-4-benzyloxy-2-(1'-benzyloxy-4'-hydroxybutyl)pyrrolidine 
• 220475-19-4 (2S,4R,1'R)-N-benzyl-4-benzyloxy-2-(1'-benzyloxy-3'-butenyl)pyrrolidine 
• 220475-16-1 (2S,4R,1'R)-N-benzyl-4-benzyloxy-2-(1'-hydroxy-3'-butenyl)pyrrolidine 
• 220475-08-1 (2S,4R)-N-benzyl-4-benzyloxy-2-formylpyrrolidine 
• 220475-07-0 (2S,4R)-N-benzyl-2-hydroxymethyl-4-benzyloxypyrrolidine 

Relevant academic research and scientific papers

ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND

To provide a method for treating cancer using a pyrazolo[3,4-d]pyrimidine compound or a salt thereof. The present invention provides an antitumor agent comprising a pyrazolo[3,4-d]pyrimidine compound of formula (I) wherein X, Y, Z1, Z2/su

NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF

To provide a novel compound having a HER2 inhibitory effect and having a cytostatic effect. It is also intended to provide a medicament useful in the prevention and/or treatment of a disease involving HER2, particularly, cancer, on the basis of the HER2 i

Synthesis and activity as a glycosidase inhibitor of 2,8-dihydroxyindolizidines

The synthesis and enzyme assay of 2,8-dihydroxyindolizidines (5) were described. Four diastereomers of these were prepared from trans-4-hydroxy-L-proline (6) which is commercially available amino acid. Among synthetic compounds 5a1 and 5b2 showed medium potent inhibition to α-amyloglycosidase, while 5a2 displayed medium activity to α-glucosidase.